Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
EBOS Group Limited ( (AU:EBO) ) just unveiled an announcement.
S&P Dow Jones Indices has announced its March 2026 quarterly rebalance of the S&P/ASX indices, bringing notable shifts across the major Australian benchmarks, including the S&P/ASX 20, 50, 100, 200 and 300. Changes reflect evolving market capitalisation and liquidity, with several resource-focused companies gaining prominence while some established names are removed.
In the S&P/ASX 200, EBOS Group Limited will be removed alongside Catapult Sports and DigiCo Infrastructure REIT, while Predictive Discovery, SRG Global and Vulcan Energy Resources are added, potentially affecting index-tracking funds and liquidity for these stocks. Across other indices, Northern Star Resources enters the top-tier S&P/ASX 20, additional gold and resource names join the S&P/ASX 50 and 100, and a broad mix of emerging miners, technology and industrial companies are included in the S&P/ASX 300, underscoring the growing weight of resources and growth-oriented stocks in the Australian market.
The most recent analyst rating on (AU:EBO) stock is a Buy with a A$30.00 price target. To see the full list of analyst forecasts on EBOS Group Limited stock, see the AU:EBO Stock Forecast page.
More about EBOS Group Limited
EBOS Group Limited is a diversified healthcare and pharmaceutical distribution company operating across Australia and New Zealand, supplying medicines, medical devices and animal care products to pharmacies, hospitals and veterinary clinics. It plays a key role in regional healthcare supply chains and is a significant component of the local listed healthcare sector.
Average Trading Volume: 145,262
Technical Sentiment Signal: Sell
Current Market Cap: A$4.08B
For a thorough assessment of EBO stock, go to TipRanks’ Stock Analysis page.